Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Proteomes ; 4(4)2016 Oct 14.
Article in English | MEDLINE | ID: mdl-28248240

ABSTRACT

(1) Oxaliplatin-based chemotherapy for colorectal cancer liver metastasis is associated with sinusoidal injury of liver parenchyma. The effects of oxaliplatin-induced liver injury on the protein level remain unknown. (2) Protein expression in liver tissue was analyzed-from eight patients treated with FOLFOX (combination of fluorouracil, leucovorin, and oxaliplatin) and seven controls-by label-free liquid chromatography mass spectrometry. Recursive feature elimination-support vector machine and Welch t-test were used to identify classifying and relevantly changed proteins, respectively. Resulting proteins were analyzed for associations with gene ontology categories and pathways. (3) A total of 5891 proteins were detected. A set of 184 (3.1%) proteins classified the groups with a 20% error rate, but relevant change was observed only in 55 (0.9%) proteins. The classifying proteins were associated with changes in DNA replication (p < 0.05) through upregulation of the minichromosome maintenance complex and with the innate immune response (p < 0.05). The importance of DNA replication changes was supported by the results of Welch t-test (p < 0.05). (4) Six weeks after FOLFOX treatment, less than 1% of identified proteins showed changes in expression associated with DNA replication, cell cycle entry, and innate immune response. We hypothesize that the changes remain after recovery from FOLFOX treatment injury.

2.
Appl Health Econ Health Policy ; 11(6): 577-92, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24166193

ABSTRACT

OBJECTIVES: On the basis of a systematic review, we aimed to establish the cost and drivers of cost and/or resource use of intra- and perioperative complications occurring as a result of selected major surgical procedures, as well as to understand the relationship between costs and severity of complication and, consequently, the economic burden they represent. We also assessed the clinical and economic methodologies used to derive costs and resource use across the studies with a view to providing guidance on reporting standards for these studies. METHODS: We searched EMBASE, MEDLINE and Econlit (from 2002 to 2012) for study publications including resource use/cost data relating to surgical complications. RESULTS: We identified 38 relevant studies on pancreatic (n = 14), urologic (n = 4), gynaecological (n = 6), thoracic (n = 13) and hepatic surgery (n = 1). All studies showed that complications lead to higher resource use and hospital costs compared with surgical procedures without complications. Costs depend on type of complication and complication severity, and are driven primarily by prolonged hospitalisation. There was considerable heterogeneity between studies with regard to patient populations, outcomes and procedures, as well as a lack of consistency and transparency of reporting of costs/resource use. Complication severity grading systems were used infrequently. CONCLUSIONS: The overall conclusions of included studies are consistent: complications represent an important economic burden for health care providers. We conclude that more accurate and consistent data collection is required to serve as input for good-quality economic analyses, which in turn can inform hospital decisions on cost-efficient allocation of their limited resources.


Subject(s)
Costs and Cost Analysis/economics , Intraoperative Complications/economics , Postoperative Complications/economics , Surgical Procedures, Operative/economics , Health Resources/economics , Health Resources/statistics & numerical data , Humans , Length of Stay/economics , Severity of Illness Index
4.
HPB (Oxford) ; 15(4): 265-72, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23458313

ABSTRACT

OBJECTIVES: Sinusoidal injury (SI) after oxaliplatin-based therapies for colorectal liver metastasis (CRLM) can increase postoperative morbidity. Preoperative methods to estimate SI are lacking. The aim of this study was to identify SI by evaluating portal vein haemodynamics. METHODS: Magnetic resonance imaging flowmetry (MRIF) was used to estimate portal vein haemodynamics in 29 patients with CRLM before liver surgery. Sinusoidal injury was evaluated from resected non-tumorous liver parenchyma according to the combined vascular injury (CVI) score of ≥3. RESULTS: All patients with SI (six of 29) received oxaliplatin; however, a significant association could not be proven (P= 0.148). Oxaliplatin-treated patients showed portal vein dilatation in both the SI and non-SI groups compared with patients who had not received oxaliplatin (Bonferroni corrected P= 0.003 and P= 0.039, respectively). Mean portal velocity tended to be lower in patients with SI compared with oxaliplatin-treated patients without SI (Bonferroni corrected P= 0.087). A mean portal velocity of ≤14.35 cm/s together with a cross-section area of ≥1.55 cm(2) was found to predict SI with sensitivity of 100% and specificity of 78%. CONCLUSIONS: Oxaliplatin treatment was associated with portal vein dilatation. Patients with SI showed a tendency towards decreased mean portal flow velocity. This may indicate that SI is associated with an increased resistance to blood flow in the liver parenchyma. Portal vein haemodynamic variables estimated by MRIF can identify patients without SI non-invasively.


Subject(s)
Antineoplastic Agents/adverse effects , Colorectal Neoplasms/drug therapy , Liver Neoplasms/drug therapy , Magnetic Resonance Imaging , Organoplatinum Compounds/adverse effects , Portal Vein/drug effects , Aged , Antineoplastic Agents/therapeutic use , Blood Flow Velocity , Chemotherapy, Adjuvant , Colorectal Neoplasms/pathology , Colorectal Neoplasms/physiopathology , Dilatation, Pathologic/etiology , Female , Humans , Liver Neoplasms/physiopathology , Liver Neoplasms/secondary , Male , Middle Aged , Organoplatinum Compounds/therapeutic use , Oxaliplatin , Portal Vein/pathology , Predictive Value of Tests , Prospective Studies , Sensitivity and Specificity
5.
Acta Oncol ; 52(4): 824-30, 2013 May.
Article in English | MEDLINE | ID: mdl-22974074

ABSTRACT

BACKGROUND: The aim was to evaluate the feasibility and the effectiveness of neoadjuvant systemic chemotherapy followed by cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC) in patients with peritoneal carcinomatosis (PC) from gastric cancer. MATERIAL AND METHODS: Eighteen patients (median age 57 years, range 38-74) were scheduled for three months' neoadjuvant systemic chemotherapy followed by CRS + HIPEC + EPIC. RESULTS: At the time of surgery, the peritoneal tumor burden was extensive with tumor growth on the entire peritoneal cavity. Only eight patients received the entire treatment and OS was 14.3 months (range 6.1-34.3, 95% CI 6.6-20.3). Six patients had macroscopically radical (CC0) surgery and for this subgroup OS was 19.1 months (range 6.1-34.3, 95% CI 6.9-27.1). Postoperative 90-day mortality was 10% (one patient) and the perioperative grades II-IV adverse events (AE) rate was 62.5%. DISCUSSION: Neoadjuvant chemotherapy followed by CRS + HIPEC + EPIC does not seem to be associated with prolonged OS in patients with extensive PC growth from gastric cancer unless macroscopically radical surgery is achieved. However, morbidity from this treatment is considerable and it cannot be recommended for routine care until a prospective randomized trial has been performed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma/drug therapy , Carcinoma/surgery , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/surgery , Stomach Neoplasms/drug therapy , Stomach Neoplasms/surgery , Administration, Intravenous , Adult , Aged , Carcinoma/secondary , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Humans , Injections, Intraperitoneal , Male , Middle Aged , Peritoneal Neoplasms/secondary , Peritoneum/surgery , Stomach Neoplasms/pathology
6.
J Med Chem ; 55(10): 4740-63, 2012 May 24.
Article in English | MEDLINE | ID: mdl-22541068

ABSTRACT

The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions. Predicting potential interactions with OATPs is, therefore, of value. Here, we developed in vitro and in silico models for identification and prediction of specific and general inhibitors of OATP1B1, OATP1B3, and OATP2B1. The maximal transport activity (MTA) of each OATP in human liver was predicted from transport kinetics and protein quantification. We then used MTA to predict the effects of a subset of inhibitors on atorvastatin uptake in vivo. Using a data set of 225 drug-like compounds, 91 OATP inhibitors were identified. In silico models indicated that lipophilicity and polar surface area are key molecular features of OATP inhibition. MTA predictions identified OATP1B1 and OATP1B3 as major determinants of atorvastatin uptake in vivo. The relative contributions to overall hepatic uptake varied with isoform specificities of the inhibitors.


Subject(s)
Drug Interactions , Liver/metabolism , Models, Molecular , Organic Anion Transporters, Sodium-Independent/antagonists & inhibitors , Organic Anion Transporters/antagonists & inhibitors , Atorvastatin , Biological Transport/drug effects , Estradiol/analogs & derivatives , Estradiol/pharmacokinetics , Estrone/analogs & derivatives , Estrone/pharmacokinetics , HEK293 Cells , Heptanoic Acids/pharmacokinetics , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , In Vitro Techniques , Least-Squares Analysis , Liver-Specific Organic Anion Transporter 1 , Multivariate Analysis , Organic Anion Transporters/genetics , Organic Anion Transporters/metabolism , Organic Anion Transporters, Sodium-Independent/genetics , Organic Anion Transporters, Sodium-Independent/metabolism , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Pyrroles/pharmacokinetics , Solute Carrier Organic Anion Transporter Family Member 1B3 , Structure-Activity Relationship , Transfection
7.
J Hepatol ; 56(3): 640-6, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22027576

ABSTRACT

BACKGROUND & AIMS: Neoadjuvant chemotherapy prior to liver surgery for colorectal metastases can cause marked steatosis (≥ 33%) and steatohepatitis defined by non-alcoholic fatty liver disease activity score (NAS) as adverse effects on liver parenchyma. The aim of this study was to evaluate the steatosis level prior to liver resection using proton magnetic resonance spectroscopy ((1)H MRS) and to compare it with digital quantification of steatosis (DQS) and "classical" histopathology. METHODS: (1)H MRS at 3T evaluated steatosis in 35 patients with colorectal liver metastasis, planned for liver resection. Non-tumorous liver parenchyma samples were obtained after surgery for classical histopathology and DQS utilising automated software for quantification of histopathological slides using image processing. RESULTS: Classical histopathology defined marked steatosis in nine patients. Histopathology was less reliable than DQS (interclass correlation coefficient - ICC 0.771) or (1)H MRS (ICC 0.722) in steatosis estimation. (1)H MRS showed very similar steatosis levels and high reliability compared to DQS (ICC 0.955). Steatohepatitis was observed in seven patients (NAS ≥ 4) and (1)H MRS was able to predict it with 100% sensitivity and 89% specificity at threshold 10.9%, without knowing lobular inflammation or hepatocyte ballooning. BMI was significantly higher in the groups with marked steatosis and steatohepatitis. Standard blood tests or chemotherapy had no predictive value. CONCLUSIONS: (1)H MRS is a reliable non-invasive tool for steatosis assessment, and interestingly, it was able to predict steatohepatitis defined by NAS ≥ 4 in patients planned for liver resection of colorectal metastases after neoadjuvant chemotherapy.


Subject(s)
Colorectal Neoplasms/pathology , Fatty Liver/pathology , Liver Neoplasms/secondary , Liver/pathology , Magnetic Resonance Imaging/methods , Magnetic Resonance Imaging/standards , Aged , Female , Humans , Liver Cirrhosis/pathology , Male , Middle Aged , Predictive Value of Tests , Preoperative Care/methods , Preoperative Care/standards , Prospective Studies , Protons , Reproducibility of Results , Severity of Illness Index
10.
Transplantation ; 91(6): 632-8, 2011 Mar 27.
Article in English | MEDLINE | ID: mdl-21289595

ABSTRACT

BACKGROUND: Hepatocyte transplantation (HcTx) has proven to be a safe procedure, although the functional results have been unsatisfactory, probably due to insufficient engraftment or a loss of transplanted mass or function. In this study, we investigate whether hepatocytes in contact with blood induce an inflammatory reaction leading to, similar to what happens in clinical islet transplantation, an instant blood-mediated inflammatory reaction (IBMIR) resulting in an early loss of transplanted cells. METHODS: By using an experimental model that mimics the portal vein blood flow, we could study different parameters reflecting the effects on the innate immunity elicited by hepatocytes in contact with ABO-matched human blood. RESULTS: We report that all aspects of the IBMIR such as platelet and granulocyte consumption, coagulation, and complement activation were demonstrated. Addition of various specific inhibitors of coagulation allowed us to clearly delineate the various stages of the hepatocyte-triggered IBMIR and show that the reaction was triggered by tissue factor. Analysis of a case of clinical HcTx showed that hepatocyte-induced IBMIR also occurs in vivo. Both the inflammatory and the coagulation aspects were controlled by low-molecular-weight dextran sulfate. CONCLUSION: Isolated hepatocytes in contact with blood induce the IBMIR in vitro, and there are indications that these events are also relevant in vivo. According to these findings, HcTx would benefit from controlling a wider range of signals from the innate immune system.


Subject(s)
Hepatocytes/immunology , Hepatocytes/transplantation , Inflammation/etiology , Postoperative Complications/etiology , ABO Blood-Group System , Blood Coagulation , Cells, Cultured , Dextran Sulfate/pharmacology , Humans , Immunohistochemistry , Inflammation/prevention & control , Thromboplastin/physiology
11.
HPB (Oxford) ; 12(9): 637-43, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20961372

ABSTRACT

BACKGROUND: Transarterial chemotherapy infusion (TAI) with lipiodol is a palliative treatment for hepatocellular carcinoma. The aim of this study was to describe the outcomes of TAI from a single scandinavian centre between 1995 to 2008. METHODS: The study is a retrospective analyse of prospectively collected data. TAI (doxorubicin, 50 mg with lipiodol) was administrated every 6 weeks. After 5 treatments, a CT scan was performed, and if the disease was stable, (RECIST score) treatment was continued. RESULTS: 57 patients with HCC were treated with TAI. Median age; 72 years (52-84), 41 (71%) men. 52 (91%) had Child-Pugh score A, and 5 (9%) had Child-Pugh B. Nine (16%) patients had a BCLC score A, 19 (33%) B, 29 (51%) C, while none was classified as BCLC D. Twenty nine (51%) patients had a tumour size ≥ 10 cm. In total 254 treatments were performed, a median of 4 (1-20) per patient. Treatment mortality was 0%. In 30 (53%) patients the treatment strategy was not completed due to deteriorating clinical conditions. Median survival was 17 months (2-108), 2, 3, and 5-years survival was 34%, 22%, and 13%, respectively. Patients that responded to treatment (n = 23) had a median survival of 26 (13-108) months compared to 8 (2-48) months for those not fulfilling the treatment plan, p < 0.05. Tumour size ≥ 10 cm, AFP ≥ 400 µg/l, and Child-Pugh class B or C were negative prognostic factors for survival, p < 0.05. CONCLUSIONS: The 5 year survival was 13%, and median survival 17 months. Treatment mortality was 0%. Patients that responded to treatment (40%) had a median survival of 26 months. TAI provides good palliation but selection of patients is crucial.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic , Doxorubicin/administration & dosage , Ethiodized Oil/administration & dosage , Liver Neoplasms/therapy , Aged , Aged, 80 and over , Antibiotics, Antineoplastic/adverse effects , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/mortality , Chemoembolization, Therapeutic/adverse effects , Doxorubicin/adverse effects , Ethiodized Oil/adverse effects , Female , Humans , Infusions, Intra-Arterial , Kaplan-Meier Estimate , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/mortality , Male , Middle Aged , Palliative Care , Patient Selection , Registries , Retrospective Studies , Survival Rate , Sweden , Time Factors , Tomography, X-Ray Computed , Treatment Outcome
14.
J Gastrointest Surg ; 12(7): 1283-7, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18278534

ABSTRACT

A right hemihepatectomy is frequently required for surgical removal of colorectal liver metastases. Today, this procedure can be performed quite safely provided the remaining liver is free from significant disease including steatohepatitis due to prolonged cytostatic treatment. Standard surgical techniques for liver resection are described in surgical textbooks. However, each center has developed its own modifications of important details. In this paper, we describe our technique to resect the right liver lobe using conventional surgical techniques as well as a vascular stapler and an ultrasonic dissector. This technique has proven to be quite safe, and blood loss is most often not significant despite we do not routinely apply the Pringle's manoeuvre during the division of the liver parenchyma.


Subject(s)
Colorectal Neoplasms/pathology , Hepatectomy/methods , Liver Neoplasms/surgery , Colorectal Neoplasms/diagnostic imaging , Colorectal Neoplasms/surgery , Humans , Liver Neoplasms/diagnosis , Liver Neoplasms/secondary , Treatment Outcome , Ultrasonography
15.
Scand J Gastroenterol ; 42(1): 94-102, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17190769

ABSTRACT

OBJECTIVE: Surgery in patients with malignant obstructive jaundice is associated with increased risks for postoperative septic complications. The aim of this study was to investigate the inflammatory and the local cellular immune response in patients accepted for surgery because of tumours in the hepatic-pancreatic-biliary (HPB) tract. MATERIAL AND METHODS: Patients with obstructive jaundice (group HPB(+)) were compared with those without (HPB(-)). Patients undergoing surgery for benign abdominal disorders served as controls. Obstructive jaundice was present in 18 out of 33 HPB patients. Preoperatively, blood was analysed for bacteria, endotoxins and cytokines (TNF-alpha, IL-6 and IL-10). At operation, mesenteric lymph nodes (MLNs) were excised for bacterial cultures using standard microbiological techniques, and immunohistochemistry, using antibodies CD4 and CD8 (mainly staining T lymphocytes), CD68 (macrophages), and anti-caspase-3 (to determine the rate of apoptosis). RESULTS: Bacterial translocation was not demonstrated in any of the patients. Increased preoperative concentrations of endotoxins were found in group HPB(+). The number of macrophages and the rate of apoptosis in MLNs were increased in jaundiced patients, while the number of T lymphocytes was decreased. CONCLUSIONS: Malignant obstructive jaundice causes increased blood concentrations of endotoxins and cytokines, an increased number of macrophages in MLNs, a higher rate of apoptosis in MLNs, but a decreased number of T lymphocytes in MLNs. The lymphocyte depletion is probably due to the increased rate of apoptosis, and might reduce the ability of jaundiced patients to eradicate infection.


Subject(s)
Digestive System Neoplasms/complications , Jaundice, Obstructive/immunology , Adult , Aged , Aged, 80 and over , Apoptosis , Bacteria/isolation & purification , CD4 Lymphocyte Count , CD8-Positive T-Lymphocytes , Cytokines/blood , Endotoxins/blood , Female , Humans , Immunohistochemistry , Jaundice, Obstructive/etiology , Jaundice, Obstructive/microbiology , Jaundice, Obstructive/pathology , Lymph Nodes/microbiology , Lymph Nodes/pathology , Macrophages/pathology , Male , Mesentery , Middle Aged , T-Lymphocytes/pathology
16.
Shock ; 25(2): 147-54, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16525353

ABSTRACT

The aim of this study was to determine if cyclooxygenase (COX) inhibitors influence immune cell distribution in the small intestinal mucosa and mesenteric lymph nodes (MLNs), the grade of mucosal damage, and the rate of apoptosis in septic rats. The effects induced by a selective COX-2 inhibitor (SC-236) were compared with those of a nonselective COX-1 and -2 inhibitor (indomethacin). Cecal ligation and puncture (CLP), CLP + SC-236 p.o, and CLP + indomethacin p.o, were evaluated. Animals were harvested 6 and 24 h after CLP, respectively. The concentration of proinflammatory cytokines was higher in ascitic fluid than in blood. CLP + SC-236 attenuated IL-6 in plasma and in ascitic fluid and CLP + indomethacin augmented TNF-alpha in ascitic fluid compared with CLP at 6 h. CLP + SC-236 gave a lesser degree of mucosal damage compared with CLP alone or with indomethacin at 6 and 24 h (P < 0.05). Untreated CLP had significant reductions in the number of T lymphocytes in the villi and increases of macrophages in the mucosa and MLNs compared with controls (P < 0.05). CLP + indomethacin decreased T lymphocytes in the villi and MLNs. CLP caused an enhanced apoptosis in the mucosa compared with controls (P < 0.05), pretreatment with COX inhibitors did not significantly change this. Both COX inhibitors enhanced apoptosis in MLNs and attenuated the increase of macrophages in mucosa and MLNs (P < 0.05). It is proposed that the increased apoptosis and the decrease in T cells in the mucosa may be causally related. Apoptosis of lymphocytes may impair the immunologic defense in sepsis. Furthermore, loss of intestinal epithelial cells may compromise bowel wall integrity and facilitate translocation.


Subject(s)
Apoptosis/drug effects , Cyclooxygenase Inhibitors/administration & dosage , Immunity, Mucosal/drug effects , Indomethacin/administration & dosage , Pyrazoles/administration & dosage , Sepsis/immunology , Sulfonamides/administration & dosage , Animals , Cyclooxygenase 1/immunology , Cyclooxygenase 2/immunology , Disease Models, Animal , Interleukin-6/immunology , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Intestine, Small/immunology , Intestine, Small/pathology , Male , Membrane Proteins/antagonists & inhibitors , Membrane Proteins/immunology , Mesentery/immunology , Mesentery/pathology , Rats , Rats, Wistar , Sepsis/drug therapy , Sepsis/pathology , T-Lymphocytes/immunology , T-Lymphocytes/pathology , Time Factors , Tumor Necrosis Factor-alpha/immunology
SELECTION OF CITATIONS
SEARCH DETAIL